Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹607.00
₹14.40(2.38%)
At close: 4:00 PM EDT
₹607.00
₹14.40(2.38%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹913.50
Previous CloseN/A
Volume305.42K
Average Volume (3M)38.83K
Market Cap
₹176.04B
Enterprise Value₹74.34K
Total Cash (Recent Filing)₹451.80M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)59.5
Beta0.76
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.06%
Share Statistics
EPS (TTM)15.20
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.08
Revenue Forecast (FY)₹19.09B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability RecoveryThe FY2026 rebound indicates stronger product economics and operating execution after the FY2023 weakness. Higher margins provide a better base for funding product commercialization and absorbing cost pressures, although consistency remains important.
Conservative LeverageLower leverage reduces financial risk and interest burden while preserving capacity to support manufacturing investment and growth initiatives. The expanding equity and asset base also suggests improved balance-sheet resilience compared with earlier periods.
Complex Pharmaceutical And Contract Manufacturing ExposureExposure to APIs, complex formulations, oncology, and contract manufacturing gives Shilpa Medicare several routes to serve pharmaceutical customers. These capabilities can support recurring demand and commercialization opportunities beyond a single product category.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow means reported earnings are not translating into surplus cash after investment needs. This can increase reliance on working-capital funding or external capital and may constrain the pace of sustainable expansion.
Volatile Earnings And Gross MarginsMargin volatility makes the recent profitability recovery less predictable and complicates long-term earnings forecasting. A lower gross margin can limit operating leverage if pricing, product mix, input costs, or manufacturing utilization become less favorable.
Historically Weak Return On EquityLow or negative historical ROE indicates that the enlarged capital base has not consistently produced strong shareholder returns. Until the FY2026 improvement is confirmed through reported ROE, capital efficiency remains an unresolved structural concern.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹913.50 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹176.04B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Nov 06, 2026 which is in 69 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Aug 05, 2026. The company reported ₹5.18 earnings per share for the quarter, beating the consensus estimate of ₹4 by ₹1.18.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of 0.06%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹5.18 in its last earnings report, beating expectations of ₹4. Following the earnings report the stock price went up 11.251%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―